Download PDF
Nervenheilkunde 2022; 41(03): 176-182
DOI: 10.1055/a-1740-5720
Übersichtsartikel

Neu aufgetretener täglicher Kopfschmerz

Eine (neue) KopfschmerzentitätNew daily persistent headacheA (new) headache entity
Stefan Evers
1   Klinik für Neurologie, Krankenhaus Lindenbrunn, Coppenbrügge
2   Medizinische Fakultät, Universität Münster
› Author Affiliations
› Further Information
    Permissions and Reprints

ZUSAMMENFASSUNG

Der neu aufgetretene tägliche Kopfschmerz (englisch: new daily persistent headache, NDPH) ist 2004 als eigenständiger idiopathischer Kopfschmerz in die International Classification of Headache Disorders aufgenommen worden. Er ist wenig bekannt, obwohl die Prävalenz in etwa der des Clusterkopfschmerzes entspricht. Der Kopfschmerz ist definiert durch seinen plötzlichen Beginn innerhalb eines Tages und das seitdem ununterbrochene Auftreten ohne jegliche Pause. Der Kopfschmerz selbst ist unspezifisch und meistens von mittlerer Intensität. Die Pathophysiologie ist gänzlich unbekannt, obwohl eine postinfektiöse Genese immer wieder postuliert worden ist. Ein weiteres Merkmal ist das sehr schlechte Ansprechen auf sämtliche Therapieverfahren. Die Therapie ist dementsprechend rein empirisch; intravenöse Infusionen mit Lidocain oder Ketamin scheinen die beste, aber nur eine kurz anhaltende Wirksamkeit zu zeigen. Botulinumtoxin ist ebenfalls in einigen Fällen als wirksam beschrieben worden. Orale Therapieversuche scheitern sehr häufig. Wichtig für die Betroffenen ist es vor allem, eine korrekte Diagnose zu erhalten und zu lernen, mit dem Kopfschmerz umzugehen.

ABSTRACT

The new daily persistent headache (NDPH) has been implemented as a separate headache disorder in the International Classification of Headache Disorders in 2004. It is hardly known, although the prevalence is about as high as for cluster headache. The headache is defined by its sudden onset within one day and by the persistent pain from then on without any break. The headache itself is unspecific and often of moderate intensity. The pathophysiology is completely unknown, although a postinfectious aetiology has been discussed. A further typical feature is the very poor efficacy of all therapeutic procedures. Treatment is empiric; intravenous infusions with lidocaine or ketamin seem to have the best although only short lasting efficacy. Botulinumtoxin has been described as efficacious in some cases. Oral drug treatment is almost always without benefit. It is important for the sufferers to receive a correct diagnosis and to learn how to cope with this headache disorder.

Schlüsselwörter

Neu aufgetretener täglicher Kopfschmerz - idiopathische Kopfschmerzen - Therapieresistenz

Key words

New daily persistent headache - idiopathic headache - refractory to treatment


Publication History

Article published online:
03 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Yamani N, Olesen J. New daily persistent hedache: a systematic review on an enigmatic disorder. J Headache Pain 2019; 20: 80
    CrossrefPubMedGoogle Scholar
  • 2 Vanast WJ. New daily persistent headaches: definition of a benign syndrome. Headache 1986; 26: 317
    Google Scholar
  • 3 Robbins MS, Vanast WJ, Purdy RA. New daily persistent headache: historical review and an interview with Dr. Walter Vanast. Headache 2017; 57: 926-934
    CrossrefPubMedGoogle Scholar
  • 4 Rozen TD. Daily persistent headache after a viral illness during a worldwide pandemic may not be a new occurrence: Lessons from the 1890 Russian/Asiatic flu. Cephalalgia 2020; 40: 1406-1409
    CrossrefPubMedGoogle Scholar
  • 5 Silberstein SD, Lipton RB, Solomon S. et al Classification of daily and near daily headaches: proposed revision to the IHS criteria. Headache 1994; 34: 1-7
    CrossrefPubMedGoogle Scholar
  • 6 Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 (Suppl. 01) 9-160
    CrossrefPubMedGoogle Scholar
  • 7 Peng KP, Fuh JL, Yuan HK. et al New daily persistent headache: Should migrainous features be incorporated?. Cephalalgia 2011; 31: 1561-1569
    CrossrefPubMedGoogle Scholar
  • 8 Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3 rd edition. Cephalalgia 2018; 38: 1-211
    CrossrefPubMedGoogle Scholar
  • 9 Evans RW, Turner DP. Clinical features of new daily persistent headache: A retrospective chart review of 328 cases. Headache 2021; 61: 1529-1538
    CrossrefPubMedGoogle Scholar
  • 10 Goadsby PJ. New daily persistent headache: a syndrome, not a discrete disorder. Headache 2011; 51: 650-653
    CrossrefPubMedGoogle Scholar
  • 11 Lobo R, Wang M, Lobo S. et al Time to retire ‘New daily persistent headache’: Mode of onset of chronic migraine and tension-type headache. Cephalalgia. 2022 DOI: 10.1177/03331024211044440
    CrossrefPubMedGoogle Scholar
  • 12 Reidy BL, Riddle EJ, Powers SW. et al Clinic-based characterization of continuous headache in children and adolescents: Comparing youth with chronic migraine to those with new daily persistent headache. Cephalalgia 2020; 40: 1063-1069
    CrossrefPubMedGoogle Scholar
  • 13 Castillo J, Muñoz P, Guitera V. et al Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190-196
    CrossrefPubMedGoogle Scholar
  • 14 Grande RB, Aaseth K, Lundqvist C. et al Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headache. Cephalalgia 2009; 29: 1149-1155
    CrossrefPubMedGoogle Scholar
  • 15 Takase Y, Nakano M, Tatsumi C. et al Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia 2004; 24: 955-959
    CrossrefPubMedGoogle Scholar
  • 16 Bigal ME, Lipton RB, Tepper SJ. et al Primary chronic daily headache and its subtypes in adolescents and adults. Neurology 2004; 14: 843-847
    CrossrefPubMedGoogle Scholar
  • 17 Mack KJ. What incites new daily persistent headache in children?. Pediatr Neurol 2004; 31: 122-125
    CrossrefPubMedGoogle Scholar
  • 18 Kung E, Tepper SJ, Rapoport AM. et al New daily persistent headache in the pediatric population. Cephalalgia 2009; 29: 17-22
    CrossrefPubMedGoogle Scholar
  • 19 Strong E, Pierce EL, Langdon R. et al New daily persistent headache in a pediatric population. J Child Neurol 2021; 36: 888-893
    CrossrefPubMedGoogle Scholar
  • 20 Uniyal R, Paliwal VK, Tripathi A. Psychiatric comorbidity in new daily persistent headache: a cross-sectional study. Eur J Pain 2017; 21: 1031-1038
    CrossrefPubMedGoogle Scholar
  • 21 Robbins MS, Grosberg BM, Napchan U. et al Clinical and prognostic subforms of new daily-persistent headache. Neurology 2010; 74: 1358-1364
    CrossrefPubMedGoogle Scholar
  • 22 Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia 2002; 22: 66-69
    CrossrefPubMedGoogle Scholar
  • 23 Meineri P, Torre E, Rota E. et al New daily persistent headache: clinical and serological characteristics in a retrospective study. Neurol Sci 2004; 25 (Suppl. 03) S281-S282
    CrossrefPubMedGoogle Scholar
  • 24 Papetti L, Sforza G, Tarantino S. et al Features and management of new daily persistent headache in developmental-age patients. Diagnostics 2021; 11: 385
    CrossrefPubMedGoogle Scholar
  • 25 Prakash S, Saini S, Rana KR. et al Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India. J Headache Pain 2012; 13: 477-485
    CrossrefPubMedGoogle Scholar
  • 26 Rozen TD. Triggering events and new daily persistent headache: age and gender differences and insights on pathogenesis – a clinic-based study. Headache 2016; 56: 164-173
    CrossrefPubMedGoogle Scholar
  • 27 Peres MFP, Lucchetti G, Mercante JPP. et al New daily persistent headache and panic disorder. Cephalalgia 2011; 31: 250-253
    CrossrefPubMedGoogle Scholar
  • 28 Rozen TD. New daily persistent headache: an update. Curr Pain Headache Rep 2014; 18: 431
    CrossrefPubMedGoogle Scholar
  • 29 Mitsikostas D, Ashina M, Craven A. et al European headache federation consensus on technical investigation for primary headache disorders. J Headache Pain 2015; 17: 5
    CrossrefPubMedGoogle Scholar
  • 30 Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet. 1987 i (8530) 411-414
    PubMedGoogle Scholar
  • 31 Santoni JR, Santoni-Williams CJ. Headache and painful lymphadenopathy in extracranial or systemic infection: etiology of new daily persistent headaches. Intern Med 1993; 32: 530-553
    CrossrefPubMedGoogle Scholar
  • 32 Liu JWTW, de Luca RD, Mello Neto HO. et al Post-COVID-19 syndrome? New daily persistent headache in the aftermath of COVID-19. Arq Neuropsiquiatr 2020; 78: 753-754
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Dono F, Consoli S, Evangelista G. et al New daily persistent headache after SARS-CoV-2 infection: a report of two cases. Neurol Sci 2021; 42: 3965-3968
    CrossrefPubMedGoogle Scholar
  • 34 de Abreu LV, Oliveira CB, Bordini CA. et al New daily persistent headache following Dengue fever: report of three cases and an epidemiological study. Headache 2020; 60: 265-268
    CrossrefPubMedGoogle Scholar
  • 35 Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache 2007; 47: 1050-1055
    CrossrefPubMedGoogle Scholar
  • 36 Rozen TD, Roth JM, Denenberg N. Cervical spine joint hypermobility: a possible predisposing factor for new daily persistent headache. Cephalalgia 2006; 26: 1182-1185
    CrossrefPubMedGoogle Scholar
  • 37 Rozen TD. New daily persistent headache (NDPH) triggered by a single Valsalva event: A case series. Cephalalgia 2019; 39: 785-791
    CrossrefPubMedGoogle Scholar
  • 38 Naegel S, Zeller J, Hougard A. et al No structural brain alterations in new daily persistent headache – a cross sectional VBM/SBM study. Cephalalgia 2022 DOI: 10.1177/03331024211045653
    CrossrefPubMedGoogle Scholar
  • 39 Uniyal R, Chhirolya R, Tripathi A. et al Is new daily persistent headache a fallout of somatization? An observational study. Neurol Sci 2022; 43: 541-547
    CrossrefPubMedGoogle Scholar
  • 40 Prakash S, Shah ND. Post-infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain 2010; 11: 59-66
    CrossrefPubMedGoogle Scholar
  • 41 Rozen TD. Doxycycline for treatment resistant new daily persistent headache. Headache 2008; 48: S49
    Google Scholar
  • 42 Nagy AJ, Gandhi S, Bhola R. et al Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology 2011; 77: 1827-1832
    CrossrefPubMedGoogle Scholar
  • 43 Puledda F, Goadsby PJ, Prabhakar P. Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: a service evaluation. J Headache Pain 2018; 19: 5
    CrossrefPubMedGoogle Scholar
  • 44 Chan TLH. New daily persistent headache responsive to peripheral nerve blocks. Can J Neurol Sci 2022 DOI: 10.1017/cjn.2021.220
    CrossrefPubMedGoogle Scholar
  • 45 Miller S, Lagrata S, Matharu M. Multiple cranial nerve blocks for the transitional treatment of chronic headaches. Cephalalgia 2019; 39: 1488-1499
    CrossrefPubMedGoogle Scholar
  • 46 Lagrata S, Cheema S, Watkins L. et al Long-term outcomes of occipital nerve stimulation for new daily persistent headache with migrainous features. Neuromodulation 2021; 24: 1093-1099
    CrossrefPubMedGoogle Scholar
  • 47 Spears RC. Efficacy of botulinum toxin type A in new daily persistent headache. J Headache Pain 2008; 09: 405-406
    CrossrefPubMedGoogle Scholar
  • 48 Trucco M, Ruiz L. A case of new daily persistent headache treated with botulinum toxin type A. J Headache Pain 2015; 16 (Suppl. 01) A119
    CrossrefPubMedGoogle Scholar
  • 49 Joshi SG, Mathew PG, Markley HG. New daily persistent headache and potential new therapeutic agents. Curr Neurol Neurosci Rep 2014; 14: 425
    CrossrefPubMedGoogle Scholar
  • 50 Ali A, Kriegler J, Tepper S. et al New daily persistent headache and onabotulinumtoxinA therapy. Clin Neuropharmacol 2019; 42: 1-3
    CrossrefPubMedGoogle Scholar
  • 51 Marmura M, Rosen N, Abbas M. et al Intravenous Lidocaine in the treatment of refractory headache: a retrospective case series. Headache 2009; 49: 286-291
    CrossrefPubMedGoogle Scholar
  • 52 Akbar A. Response of refractory new daily persistent headache to intravenous lidocaine treatment in a pediatric patient. J Pain Relief 2017; 06: 4
    CrossrefGoogle Scholar
  • 53 Pomeroy JL, Marmura MJ, Nahas SJ. et al Ketamine infusions for treatment refractory headache. Headache 2017; 57: 276-282
    CrossrefPubMedGoogle Scholar
  • 54 Rozen TD, Beams JL. New daily persistent headache with a thunderclap headache onset and complete response to nimodipine (a new distinct subtype of NDPH). J Headache Pain 2013; 14: 100
    CrossrefPubMedGoogle Scholar
  • 55 Jamali SA, Rozen TD. An RCVS spectrum disorder? New daily persistent headache starting as a single thunderclap headache (3 new cases). Headache 2019; 59: 789-794
    CrossrefPubMedGoogle Scholar
  • 56 Rabner J, Ludwick A, LeBel A. Differences in pediatric headache prescription patterns by diagnosis. Paediatr Drugs 2018; 20: 273-284
    CrossrefPubMedGoogle Scholar
  • 57 Tariq Z, Board N, Eftimiades A. et al Resolution of new daily persistent headache by a tumor necrosis factor alpha antagonist, venlafaxine. SAGE Open Med Case Rep 2019; 07: 2050313X19847804
    Google Scholar
  • 58 Palacios-Ceña D, Talavera B, Gómez-Mayordomo V. et al Understanding the diagnoses and medical care experience of patients with new daily persistent headache: a qualitative study in Spain. BMJ Open 2021; 11: e048552
    CrossrefPubMedGoogle Scholar